Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Metformin study #11   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 15% Imp. Relative Risk, 95% CI ICU admission 2% Hospitalization 3% Wander: Prior Glucose-Lowering Medication Use and 30-Day Outcome.. c19early.com/wander.html Favors metformin Favors control
10/6 Prophylaxis study
Wander et al., Diabetes Care, doi:10.2337/dc21-1351 (Peer Reviewed)
Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19
Source   PDF   Share   Tweet
Retrospective 64,892 veterans with diabetes in the USA, showing lower mortality with existing metformin use.
risk of death, 15.0% lower, RR 0.85, p < 0.001, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
risk of ICU admission, 1.9% lower, RR 0.98, p = 0.62, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
risk of hospitalization, 3.2% lower, RR 0.97, p = 0.09, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
Wander et al., 10/6/2021, retrospective, database analysis, USA, North America, peer-reviewed, 8 authors.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical significance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit